3BILLION INC.

History

YearDetail
2016 3Billion Inc. was established and headquartered in South Korea to provide fast and accurate diagnoses after entering the rare disease genetic testing field.
2022 The company signed a Memorandum of Understanding (MoU) with Kolon Industries Future Technology Institute to expand their partnership in developing new gene therapy drugs based on its proprietary rare disease diagnosis database and artificial intelligence technology.
2024 The company collaborated with the Korea Rare Disease Foundation to enhance genetic diagnosis and counseling services for patients with developmental disabilities and autism spectrum disorders and their families.
2025 The company partnered with AstraZeneca Korea to expedite the genetic diagnosis of atypical hemolytic uremic syndrome (aHUS), a rare and life-threatening disease. The collaboration aims to reduce the diagnostic timeline from several weeks to just two weeks, ensuring patients receive timely and effective treatment.
AI Sentiment